Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
Evgen Pharma PLC (AIM: EVG) has revealed the conclusive data from its Phase 1b study, which evaluated the new enteric-coated tablet formulation of its primary drug, SFX-01.
Evgen Pharma PLC (AIM: EVG), a clinical-stage pharmaceutical development firm, has disclosed the termination of its patent and knowledge licence agreement with JuvLife Ltd, a subsidiary of Juvenescence Ltd.
First healthy volunteers dosed on schedule
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
AMTE Power and Cosworth enter partnership to develop next-generation engines for electric vehicles
AMTE Power Plc (“AMTE Power”, “AMTE” or the “Company”), the developer and manufacturer of lithium-ion and sodium-ion battery cells for specialist markets, is pleased to advise that the Board of
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma (“GBM”).